- Report
- January 2026
- 197 Pages
Global
From €3177EUR$3,545USD£2,770GBP
€3530EUR$3,939USD£3,077GBP
- Report
- January 2026
- 196 Pages
Global
From €3177EUR$3,545USD£2,770GBP
€3530EUR$3,939USD£3,077GBP
- Report
- April 2026
- 299 Pages
Global
From €5243EUR$5,850USD£4,570GBP
- Report
- February 2026
- 250 Pages
Global
From €4024EUR$4,490USD£3,508GBP
- Report
- February 2026
- 306 Pages
Global
From €2241EUR$2,500USD£1,953GBP
- Report
- October 2025
- 160 Pages
Global
From €3009EUR$3,358USD£2,623GBP
€3540EUR$3,950USD£3,086GBP
- Report
- July 2025
- 100 Pages
Global
From €3500EUR$4,183USD£3,158GBP
- Report
- February 2026
- 250 Pages
Global
From €4024EUR$4,490USD£3,508GBP
- Report
- June 2025
- 150 Pages
Global
From €3361EUR$3,750USD£2,930GBP
- Report
- June 2025
- 150 Pages
Global
From €2419EUR$2,699USD£2,109GBP
- Report
- May 2025
- 200 Pages
Global
From €2232EUR$2,490USD£1,945GBP
- Report
- April 2026
- 389 Pages
Global
From €5243EUR$5,850USD£4,570GBP
- Report
- February 2026
- 250 Pages
Global
From €4024EUR$4,490USD£3,508GBP
- Report
- February 2026
- 250 Pages
Global
From €4024EUR$4,490USD£3,508GBP
- Report
- January 2026
- 185 Pages
Global
From €4033EUR$4,500USD£3,516GBP
- Report
- July 2025
- 350 Pages
Global
From €4435EUR$4,949USD£3,867GBP
- Report
- October 2025
- 160 Pages
Global
From €3009EUR$3,358USD£2,623GBP
€3540EUR$3,950USD£3,086GBP
- Report
- April 2025
- 150 Pages
Global
From €4347EUR$4,850USD£3,789GBP
- Report
- April 2025
- 133 Pages
Global
From €16127EUR$17,995USD£14,059GBP
- Report
- April 2025
- 21 Pages
Global
From €16127EUR$17,995USD£14,059GBP

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more